4967 KOBAYASHI PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4967

TSE Prime

KOBAYASHI PHARMACEUTICAL CO.,LTD.

5,637

JPY

+84

(+1.51%)

Mar 13, 3:30 pm JST

35.36

USD

Mar 13, 2:30 am EDT

Result

PTS

outside of trading hours

5,565.2

Mar 13, 5:57 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	166,258	26,669	28,281	20,022	259.6	90	Feb 14, 2023	J-GAAP
Dec, 2023	173,455	25,780	27,330	20,338	268.2	101	Feb 9, 2024	J-GAAP
Dec, 2024	165,600	24,860	26,861	10,067	135.4	102	Feb 10, 2025	J-GAAP
Dec, 2025	165,742	14,923	16,995	3,656	49.2	104	Feb 10, 2026	J-GAAP
Dec, 2026 Guidance	173,000	12,500	13,000	10,000	134.5	106	Feb 10, 2026	J-GAAP
YoY	+4.4%	-16.2%	-23.5%	+173.5%	+173.5%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2021	Feb 1, 2021	156,000	26,000	27,800	19,500	79	J-GAAP
	Jul 29, 2021	156,000	26,000	27,800	19,500	81	J-GAAP
Results	Feb 4, 2022	155,252	26,065	28,015	19,715	83	J-GAAP
Dec, 2022	Feb 4, 2022	Available in future release
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
	Aug 8, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024
	May 10, 2024
	Aug 8, 2024
	Nov 8, 2024
Results	Feb 10, 2025
Dec, 2025	Feb 10, 2025
	Feb 3, 2026
Results	Feb 10, 2026
Dec, 2026	Feb 10, 2026	173,000	12,500	13,000	10,000	106	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2002	204,647	+10.6	Available in future release
Mar, 2003	210,922	+3.1
Mar, 2004	211,670	+0.4
Mar, 2005	215,708	+1.9
Mar, 2006	246,852	+14.4
Mar, 2007	257,022	+4.1
Mar, 2008	228,826	-11.0
Mar, 2009	125,693	-45.1
Mar, 2010	129,184	+2.8
Mar, 2011	130,824	+1.3
Mar, 2012	131,166	+0.3
Mar, 2013	121,532	-7.3
Mar, 2014	127,293	+4.7
Mar, 2015	128,344	+0.8
Mar, 2016	137,211	+6.9
Dec, 2016 Changed	120,051	－
Dec, 2017	156,761	+30.6
Dec, 2018	167,479	+6.8
Dec, 2019	158,340	-5.5
Dec, 2020	150,514	-4.9
Dec, 2021	155,252	+3.1
Dec, 2022	166,258	+7.1
Dec, 2023	173,455	+4.3
Dec, 2024	165,600	-4.5
Dec, 2025	165,742	+0.1
Dec, 2026 Guidance	173,000	+4.4	12,500	-16.2	13,000	-23.5	134.5	+173.4

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2024	165,600	24,860	15.0	4.83	3.78	0.62	135.4
Dec, 2025	165,742	14,923	9.00	1.73	1.35	0.61	49.2
Dec, 2026 Guidance	173,000	12,500	7.23	4.76	3.63	0.63	134.5

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	257,022	26,669	28,281	20,338	268.2
Fiscal Year	Mar, 2007	Dec, 2022	Dec, 2022	Dec, 2023	Dec, 2023

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2023	73,625	10,406	11,174	7,864	103.4	43	Aug 8, 2023	J-GAAP
Jan - Jun, 2024	73,136	9,471	10,434	1,436	19.3	43	Aug 8, 2024	J-GAAP
Jan - Jun, 2025	69,018	6,648	7,245	3,167	42.6	44	Aug 5, 2025	J-GAAP
Jan - Jun, 2026 Guidance	ー	ー	ー	ー	－	45	Feb 10, 2026	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2023	Feb 14, 2023	ー	ー	ー	ー	39	J-GAAP
- - - - Results	Aug 8, 2023	73,625	10,406	11,174	7,864	43	J-GAAP
Jun, 2024	Feb 9, 2024	Available in future release
Results	Aug 8, 2024
Jun, 2025	Feb 10, 2025
Results	Aug 5, 2025
Jun, 2026	Feb 10, 2026	ー	ー	ー	ー	45	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2023	25,780	-1,216	18,360	-19,576	-19,463	59,690	22.32	J-GAAP
Dec, 2024	24,860	-7,169	11,246	-18,415	-7,768	45,973	17.32	J-GAAP
Dec, 2025	14,923	25,436	25,590	-154	-7,921	64,693	23.50	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	173,455	25,780	27,330	20,338	268.2	101	Feb 9, 2024	J-GAAP
Dec, 2024	165,600	24,860	26,861	10,067	135.4	102	Feb 10, 2025	J-GAAP
Dec, 2025	165,742	14,923	16,995	3,656	49.2	104	Feb 10, 2026	J-GAAP
YoY	+0.1%	-40.0%	-36.7%	-63.7%	-63.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	36,485	5,028	5,461	976	13.1	13.8	May 10, 2024	J-GAAP
Apr - Jun, 2024	36,651	4,443	4,973	460	6.2	12.1	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	41,323	7,505	7,487	3,908	52.6	18.2	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	51,141	7,884	8,940	4,723	63.5	15.4	Feb 10, 2025	J-GAAP
Jan - Mar, 2025	32,607	2,535	2,401	1,624	21.9	7.8	May 9, 2025	J-GAAP
Apr - Jun, 2025	36,411	4,113	4,844	1,543	20.8	11.3	Aug 5, 2025	J-GAAP
Jul - Sep, 2025	43,020	4,847	5,685	3,642	49.0	11.3	Nov 11, 2025	J-GAAP
Oct - Dec, 2025	53,704	3,428	4,065	-3,153	-42.4	6.4	Feb 10, 2026	J-GAAP
YoY	+5.0%	-56.5%	-54.5%	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	30,269	-5.1	Available in future release
Apr - Jun, 2021	36,783	+7.3
Jul - Sep, 2021	40,606	+4.5
Oct - Dec, 2021	47,594	+4.7
Jan - Mar, 2022	32,646	+7.9
Apr - Jun, 2022	38,618	+5.0
Jul - Sep, 2022	43,015	+5.9
Oct - Dec, 2022	51,979	+9.2
Jan - Mar, 2023	33,467	+2.5
Apr - Jun, 2023	40,158	+4.0
Jul - Sep, 2023	45,490	+5.8
Oct - Dec, 2023	54,340	+4.5
Jan - Mar, 2024	36,485	+9.0
Apr - Jun, 2024	36,651	-8.7
Jul - Sep, 2024	41,323	-9.2
Oct - Dec, 2024	51,141	-5.9
Jan - Mar, 2025	32,607	-10.6
Apr - Jun, 2025	36,411	-0.7
Jul - Sep, 2025	43,020	+4.1
Oct - Dec, 2025	53,704	+5.0	3,428	-56.5	4,065	-54.5	-42.4	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	71,727	9,295	10,013	7,634	100.3
Fiscal Year	Dec, 2007	Sep, 2020	Sep, 2020	Sep, 2023	Sep, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Announce	Accounting Standards
Dec, 2023	2,749.17	76.4	267,473	204,370	205,681	Feb 9, 2024	J-GAAP
Dec, 2024	2,862.28	80.2	265,368	212,778	208,240	Feb 10, 2025	J-GAAP
Dec, 2025	2,827.68	76.3	275,329	210,206	204,240	Feb 10, 2026	J-GAAP

KOBAYASHI PHARMACEUTICAL CO.,LTD.(4967) Financial Results